^
BIOMARKER:

Chr del(17)(p13.1)

Chr del(17)(p13.1)
CLL
ibrutinib
Sensitive: B - Late Trials
Chr del(17)(p13.1)
CLL
rituximab + ibrutinib
Sensitive: B - Late Trials
Chr del(17)(p13.1)
CLL
acalabrutinib
Sensitive: B - Late Trials
Chr del(17)(p13.1)
CLL
alemtuzumab
Sensitive: C3 – Early Trials
Chr del(17)(p13.1)
CLL
obinutuzumab
Sensitive: C3 – Early Trials
Chr del(17)(p13.1)
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive: C3 – Early Trials